The quest for the magic bullet: Centoxin, Drotrecogin Alfa and lessons not learned

Trends in Anaesthesia and Critical Care

Volumn 3, Issue 6, 2013, Pages 316-319

  Murphy, Stephen T ^a   Bellamy, Mark C ^b  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Activated protein C; Centoxin; Drotrecogin Alfa; HA 1A; Sepsis

Indexed keywords

CENTOXIN; DROTRECOGIN; PLACEBO;

CLINICAL PRACTICE; GENETIC VARIABILITY; GRAM NEGATIVE SEPSIS; HEALTH CARE QUALITY; IMMUNOTHERAPY; INTENSIVE CARE; MICROCIRCULATION; MORTALITY; PRIORITY JOURNAL; REVIEW;

EID: 84887616888     PISSN: 22108440     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tacc.2013.05.004     Document Type: Review

References (25)

1. Lau A.S. Cytokines in the pathogenesis and treatment of infectious diseases. Adv Pediatr Infect Dis 1994, 9:211-236.
2. Giamarellos-Bourboulis E.J., Raftogiannis M. The immune response to severe bacterial infections: consequences for therapy. Expert Rev Anti Infect Ther 2012 Mar, 10(3):369-380.
3. Matsuda A., Jacob A., Wu R., Aziz M., Yang W.L., Matsutani T., et al. Novel therapeutic targets for sepsis: regulation of exaggerated inflammatory responses. JNippon Med Sch 2012, 79(1):4-18.
4. Masihi K.N. Fighting infection using immunomodulatory agents. Expert Opin Biol Ther 2001 Jul, 1(4):641-653.
5. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving sepsis Campaign guidelines committee; pediatric subgroup. Surviving sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013 Feb, 41(2):580-637.
6. Baumgartner J.D., Glauser M.P., McCutchan J.A., Ziegler E.J., van Melle G., Klauber M.R., et al. Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 1985 Jul 13, 2(8446):59-63.
7. Ziegler E.J., McCutchan J.A., Fierer J., Glauser M.P., Sadoff J.C., Douglas H., et al. Treatment of gram-negative bacteremia and shock with human antiserum to a, mutant Escherichia coli. NEngl J Med 1982 Nov 11, 307(20):1225-1230.
8. Ziegler E.J., Fisher C.J., Sprung C.L., Straube R.C., Sadoff J.C., Foulke G.E., et al. Treatment of Gram-negative bacteraemia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. NEngl J Med 1991, 324:429-436.
9. The National Committee for the Evaluation of Centoxin The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. Arch Intern Med 1994, 154:2484-2491.
10. McCloskey R.V., Straube R.C., Sanders C., Smith S.M., Smith C.R. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994, 120:1-5. The CHESS Trial Study Group.
11. Centocor hit by Centoxin withdrawal, 25th January 1993. [accessed 04.02.13]. http://www.thepharmaletter.com/file/53878/centocor-hit-by-centoxin-withdrawal.html.
12. Esmon C.T., Taylor F.B., Snow T.R. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991 Jul 12, 66(1):160-165.
13. Fourrier F., Chopin C., Goudemand J., Hendrycx S., Caron C., Rime A., et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992 Mar, 101(3):816-823.
14. Bernard G.R., Vincent J.-L., Laterre P.-F., LaRosa S.P., Dhainaut J.-F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. NEngl J Med 2001, 344:699-709.
15. Anti-Infective Drugs Advisory Committee meeting. Rockville, Md.: Food and Drug Administration, October 16, 2001. [accessed 04.02.13]. http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3797t1.doc.
16. FDA briefing document: anti-infective advisory committee Drotrecogin alfa (activated), [recombinant human activated protein c (rhapc)] Xigris™ Bla # 125029/0 September 12, 2001. [accessed 04.02.13]. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.doc.
17. Siegel J.P. Assessing the use of activated protein C in the treatment of severe sepsis. NEngl J Med 2002 Sep 26, 347(13):1030-1034.
18. Abraham E., Laterre P.-F., Garg R., Levy H., Talwar D., Trzaskoma B.L., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. NEngl J Med 2005, 353:1332-1341.
19. Nadel S., Goldstein B., Williams M.D., Dalton H., Peters M., Macias W.L., et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836-843.
20. Ranieri V.M., Thompson B.T., Barie P.S., Dhainaut J.-F., Douglas I.S., Finfer S., et al. Drotrecogin alfa (activated) in adults with septic shock. NEngl J Med 2012, 366:2055-2064. the PROWESS- SHOCK Study Group.
21. FDA drug safety communication: voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit 25th October 2011, [accessed 04.02.13]. http://www.fda.gov/Drugs/DrugSafety/ucm277114.htm.
22. Reason James Human error 1990, Cambridge University Press, Cambridge.
23. Quezado Z.M., Natanson C., Hoffman W.D. Looking back on HA-1A. Arch Intern Med 1994 Nov 14, 154(21):2393.
24. Ridley S., Wyncoll D. The withdrawal of Xigris. JICS 2012, 13:7-9.
25. Lilford R.J., Braunholtz D. For debate: the statistical basis of public policy: a paradigm shift is overdue. BMJ 1996, 313:603-607.